DK0827408T3 - Fremgangsmåde til administration af IGF-I - Google Patents

Fremgangsmåde til administration af IGF-I

Info

Publication number
DK0827408T3
DK0827408T3 DK96915698T DK96915698T DK0827408T3 DK 0827408 T3 DK0827408 T3 DK 0827408T3 DK 96915698 T DK96915698 T DK 96915698T DK 96915698 T DK96915698 T DK 96915698T DK 0827408 T3 DK0827408 T3 DK 0827408T3
Authority
DK
Denmark
Prior art keywords
administration
mammal
igf
period
time
Prior art date
Application number
DK96915698T
Other languages
English (en)
Inventor
Neil Gesundheit
Marc R Hammerman
Ross G Clark
Steven B Miller
Original Assignee
Genentech Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Washington filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0827408T3 publication Critical patent/DK0827408T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK96915698T 1995-05-22 1996-05-09 Fremgangsmåde til administration af IGF-I DK0827408T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/445,805 US5741776A (en) 1995-05-22 1995-05-22 Method of administration of IGF-I
PCT/US1996/006704 WO1996037216A1 (en) 1995-05-22 1996-05-09 Method of administration of igf-i

Publications (1)

Publication Number Publication Date
DK0827408T3 true DK0827408T3 (da) 2007-02-26

Family

ID=23770265

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96915698T DK0827408T3 (da) 1995-05-22 1996-05-09 Fremgangsmåde til administration af IGF-I

Country Status (16)

Country Link
US (1) US5741776A (da)
EP (1) EP0827408B1 (da)
JP (2) JPH11505265A (da)
AT (1) ATE343395T1 (da)
AU (1) AU699113B2 (da)
CA (1) CA2218018A1 (da)
DE (1) DE69636654T2 (da)
DK (1) DK0827408T3 (da)
ES (1) ES2275276T3 (da)
HK (1) HK1009744A1 (da)
IL (1) IL118356A0 (da)
MX (1) MX9708918A (da)
NZ (1) NZ307913A (da)
PT (1) PT827408E (da)
WO (1) WO1996037216A1 (da)
ZA (1) ZA963995B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
ZA978334B (en) * 1996-09-16 1999-03-16 Univ Dalhousie Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
US6403764B1 (en) * 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
WO1999051262A2 (en) 1998-04-03 1999-10-14 Chiron Corporation Use of igfi for treating articular cartilage disorders
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
DK2274978T3 (da) * 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Fremgangsmåder til behandling af en insulin-lignende vækstfaktor-I(IGF-I)-mangel
WO2006085631A2 (en) * 2005-02-08 2006-08-17 Japan As Represented By President Of National Cardiovascular Center Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
PL2510942T3 (pl) 2005-04-07 2016-02-29 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
ES2532089T3 (es) * 2005-06-02 2015-03-24 Ipsen Biopharmaceuticals, Inc. GH e IGF-1 para el tratamiento de trastornos del crecimiento
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
ES2325432B1 (es) * 2006-01-13 2010-06-09 Universidad De Malaga Utilizacion de dosis bajas de igf-i en el envejecimiento por sus efectos neuroprotectores, antioxidantes y anabolizantes.
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
ATE187889T1 (de) * 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
MD1486G2 (ro) * 1992-10-29 2001-11-30 Genentech, Inc. Metodă de tratament sau profilaxie a obezităţii
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
JPH09507832A (ja) * 1993-09-20 1997-08-12 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆｂｐ単独またはｉｇｆｂｐとｉｇｆとの複合体による免疫疾患および血液疾患の処置
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I

Also Published As

Publication number Publication date
AU699113B2 (en) 1998-11-19
ES2275276T3 (es) 2007-06-01
EP0827408A1 (en) 1998-03-11
AU5740696A (en) 1996-12-11
ATE343395T1 (de) 2006-11-15
MX9708918A (es) 1998-06-30
IL118356A0 (en) 1996-09-12
JPH11505265A (ja) 1999-05-18
DE69636654T2 (de) 2007-10-04
HK1009744A1 (en) 1999-06-11
JP2009132682A (ja) 2009-06-18
PT827408E (pt) 2007-01-31
ZA963995B (en) 1997-11-20
EP0827408B1 (en) 2006-10-25
NZ307913A (en) 2005-07-29
WO1996037216A1 (en) 1996-11-28
US5741776A (en) 1998-04-21
CA2218018A1 (en) 1996-11-28
DE69636654D1 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
DK0827408T3 (da) Fremgangsmåde til administration af IGF-I
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69221501D1 (de) Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
DK0873312T3 (da) Alfa-substituerede arylsulfonamidohydroxamsyrer som TNF-alfa- og matrix-metalloproteinaseinhibitorer
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
YU49094B (sh) Postupak za dobijanje sinergističke terapeutske kompozicije
DK0918516T3 (da) Fremgangsmåde til forebyggelse af skeletale problemer hos fjerkræ
DK0822816T3 (da) Dermatologisk præparat til behandling af actiniske keratoser
FI971711A (fi) Levobupivakaiinin ja sen analogien kiteyttäminen
ES2131528T3 (es) Nuevos polipeptidos y su uso.
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE68918944D1 (de) Künstliche rezeptor-analoge.
DK0809489T3 (da) Lægemiddelform til levering af kollagenase til sår og fremgangsmåde til dens fremstilling
DK2359854T3 (da) Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK0537313T3 (da) Arylalkylestere af 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre med terapeutisk aktivitet
EP0901873A3 (en) Liquid cristal display for laser marker
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
ATE275414T1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
SE9601264L (sv) Förfarande och anordning för håråterväxt
AT358573B (de) Verfahren zur herstellung von (1,1-dithienyl- -(3-propen-(1)-yl-(3))-(1-phenyl-1-hydroxy- propyl-2))-amin und dessen saeureadditions- salzen und optisch aktiven isomeren
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці